Evidence map›Paper›PMID 37103279›Full record

ArticleJournal of functional biomaterials2023

Inhalable Microparticles Embedding Biocompatible Magnetic Iron-Doped Hydroxyapatite Nanoparticles.

Eride Quarta, Michele Chiappi, Alessio Adamiano, Anna Tampieri, Weijie Wang, Teresa D Tetley, Francesca Buttini, Fabio Sonvico, Daniele Catalucci, Paolo Colombo and 2 more

Abstract read
In one paragraph

Article in Journal of functional biomaterials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eride QuartaDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.ORCID 0000-0003-0215-2350
Michele ChiappiNational Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 0AZ, UK.
Alessio AdamianoInstitute of Science, Technology and Sustainability for Ceramic Materials (ISSMC), National Research Council (CNR), Via Granarolo 64, 48018 Faenza, Italy.ORCID 0000-0002-2077-0411
Anna TampieriInstitute of Science, Technology and Sustainability for Ceramic Materials (ISSMC), National Research Council (CNR), Via Granarolo 64, 48018 Faenza, Italy.
Weijie WangNational Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 0AZ, UK.
Teresa D TetleyNational Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 0AZ, UK.
Francesca ButtiniDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.ORCID 0000-0002-4472-4823
Fabio SonvicoDepartment of Food and Drug, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.ORCID 0000-0001-7372-1456
Daniele CatalucciInstitute of Genetic and Biomedical Research (IRGB), National Research Council (CNR), UOS Milan and IRCCS Humanitas Research Hospital, 20089 Rozzano, Italy.ORCID 0000-0001-7041-6114
Paolo ColomboPlumeStars srl, Parco Area Delle Scienze, 27/A, 43125 Parma, Italy.
Michele IafiscoInstitute of Science, Technology and Sustainability for Ceramic Materials (ISSMC), National Research Council (CNR), Via Granarolo 64, 48018 Faenza, Italy.ORCID 0000-0002-7813-8347
Lorenzo Degli EspostiInstitute of Science, Technology and Sustainability for Ceramic Materials (ISSMC), National Research Council (CNR), Via Granarolo 64, 48018 Faenza, Italy.ORCID 0000-0002-6596-560X

Funding

European Union 720834Wellcome Trust
6 · The paper itself

Abstract

Recently, there has been increasing interest in developing biocompatible inhalable nanoparticle formulations, as they have enormous potential for treating and diagnosing lung disease. In this respect, here, we have studied superparamagnetic iron-doped calcium phosphate (in the form of hydroxyapatite) nanoparticles (FeCaP NPs) which were previously proved to be excellent materials for magnetic resonance imaging, drug delivery and hyperthermia-related applications. We have established that FeCaP NPs are not cytotoxic towards human lung alveolar epithelial type 1 (AT1) cells even at high doses, thus proving their safety for inhalation administration. Then, D-mannitol spray-dried microparticles embedding FeCaP NPs have been formulated, obtaining respirable dry powders. These microparticles were designed to achieve the best aerodynamic particle size distribution which is a critical condition for successful inhalation and deposition. The nanoparticle-in-microparticle approach resulted in the protection of FeCaP NPs, allowing their release upon microparticle dissolution, with dimensions and surface charge close to the original values. This work demonstrates the use of spray drying to provide an inhalable dry powder platform for the lung delivery of safe FeCaP NPs for magnetically driven applications.

Indexed as

hydroxyapatiteinhalable dry powdermicroparticles embedding nanoparticlesnanomedicinepulmonary diseasesuperparamagnetic nanoparticlesTrojan microparticles

Identifiers

PMID37103279
PMCPMC10145219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.